RT Journal Article
SR Electronic
T1 Long-term sequelae of Pneumococcal Sepsis in children: a systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.15.21253639
DO 10.1101/2021.03.15.21253639
A1 Ogunbameru, Adeteju
A1 Miranda, Rafael Neves
A1 Bielecki, Joanna
A1 Sander, Beate
YR 2021
UL http://medrxiv.org/content/early/2021/03/17/2021.03.15.21253639.abstract
AB Background Long-term sequelae associated with pneumococcal sepsis (PS) in pediatric patients in existing literature is currently unclear.Aim To review the evidence on sequelae and prognostic factors associated with PS among pediatric patients.Method We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines. We screened six databases from their inception to January 15, 2021. Study population were neonates, infants, children and adolescents less than 18 years old with suspected or confirmed PS disease. Outcomes included sequelae types, prognostic factors, pooled death estimate and length of hospital stay (LOS) for survivors and deceased patients. Quality of studies was assessed using Joanna Briggs Institute appraisal checklists.Results We screened 981 abstracts, and 24 full-text articles for final review. Septic shock was the most prevalent physical sequelae reported (13%, n=1492 patients). No functional, cognitive or neurological sequelae were reported in included studies. Meta-analysis of pooled mortality estimate was 14.6% (95%CI: 9.9 −19.4%). Prognostic factors associated with increased risk of PS sequelae and death included pediatric risk of mortality score ≥ 10 and co-infection with meningitis. LOS for survivors and non-survivors ranged between 5-30 days and 1-30 days. Nine included studies met at least 50% of the quality assessment criteria.Conclusion Physical sequelae and death are the PS sequelae types currently identified in existing literature. Lack of information about other possible sequelae types suggests the long-term consequences of PS disease maybe underreported, especially in resource-limited settings. Future studies should consider exploring reasons for the existing of this knowledge gap.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study did not recruit human or animal subjects and contains no individual-level data. Thus, no ethical approval was required for carrying out the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were obtained from primary literature and are publicly available to other researchers.LOSLength of Hospital stayLMICLow-and-middle-income countriesPSPneumococcal sepsis